CLV Frontier Brands Pty Ltd says it will begin marketing cannabis-flavored beers and tonics in Europe and Canada this summer, Creso Pharma, a partner in the three-way partnership, has announced.
The new drinks contain terpenes, which carry the aroma and flavor of cannabis without any accompanying THC or cannabinoids.
Creso, UK-based Baltic Beer Company Ltd. and Canadian TSX Venture incorporated LGC Capital are equal one-third partners in CLV.
‘Significant’ sales envisioned
“We see CLV as an exciting business partnership that we believe can add significant sales revenues to Creso Pharma over the coming years,” Dr. Miri Halperin Wernli, Co-Founder and CEO at Creso Pharma, said in a release.
Terpenes, which are derived from cannabis and other plants, have a range of applications in food, cosmetics, pharmaceuticals and biotechnology. Those contained in the products under development by CLV are extracted from various plant sources, all of which are food-grade, 100% natural and non-GMO, according to Creso. The terpenes are introduced to beer at the post-fermentation stage in much the same manner as hop extracts are added.
HQ’d in UK
CLV first announced in January that it would begin to develop a range of beers and tonics at newly-built facilities in the United Kingdom, where Baltic Beer Company is headquartered.
The partners said CLV will have market reach across several continents through their combined networks.
Noteworthy: Creso also announced that Canada’s TSX Venture Exchange has accepted LGC’s joint venture investment in CLV subject to LGC filing standard documentation. . . . LGC is also pursuing a deal with South Africa’s House of Hemp with whom it plans research, cultivation and commercial production of medical cannabis.
